Semaglutide cuts heart attack and stroke risk even without major weight loss, suggesting it directly benefits cardiovascular health. The discovery may shift how doctors use GLP-1 drugs beyond obesity treatment. Credit: Shutterstock A new study led by a researcher at University College London (UCL) has found that the anti-obesity medication semaglutide (Ozempic and Wegovy) may help prevent heart attacks and other major cardiovascular events, regardless of how much weight a person loses while